Smoking Cessation Treatment With Transdermal Nicotine Replacement Therapy - 1 - Tabular View

Tracking Information

First Received Date ^ICMJE

August 12, 2003

Last Updated Date

June 17, 2009

Start Date ^ICMJE

April 2003

Primary Completion Date

July 2004 (final data collection date for primary outcome measure)

Current Primary Outcome Measures ^ICMJE

Drug use
Smoking Cessation

Original Primary Outcome Measures ^ICMJE

Same as current

Change History

Complete list of historical versions of study NCT00067158 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Original Secondary Outcome Measures ^ICMJE

Descriptive Information

Brief Title ^ICMJE

Smoking Cessation Treatment With Transdermal Nicotine Replacement Therapy - 1

Official Title ^ICMJE

Smoking Cessation Treatment With Transdermal Nicotine Replacement Therapy

Brief Summary

The purpose of this study is to look at how feasible it is to incorporate a state-of-the-art smoking cessation treatment program into community substance abuse treatment programs and its impact on substance abuse and cigarette smoking.

Detailed Description

Study Phase

Phase III

Study Type ^ICMJE

Interventional

Study Design ^ICMJE

Treatment

Condition ^ICMJE

Tobacco Use Disorder

Intervention ^ICMJE

Drug: nicotine transdermal system

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

585

Completion Date

July 2004

Primary Completion Date

July 2004 (final data collection date for primary outcome measure)

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Patient is alcohol or drug dependent, in Outpatient Drug-Free or Opiate Substitute program and is interested in quitting smoking

Exclusion Criteria:

Patient is psychotic
Use of smokeless tobacco
Use of other smoking cessasation product
Pregnancy
Patient has hyper-tension, heart problems, or skin condition

Gender

Both

Ages

18 Years and older

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

United States

Administrative Information

NCT ID ^ICMJE

NCT00067158

Responsible Party

Study ID Numbers ^ICMJE

NIDA-CTN-0009-1

Study Sponsor ^ICMJE

National Institute on Drug Abuse (NIDA)

Collaborators ^ICMJE

New York University School of Medicine

Investigators ^ICMJE

Principal Investigator:

Malcolm Reid, Ph.D.

New York University

Information Provided By

National Institute on Drug Abuse (NIDA)

Verification Date

July 2008

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP